The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Open accessAbstract
INTRODUCTION: Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM's chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs. AIM: To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs. METHODS: A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included. MAIN OUTCOME MEASURE: To complete a review of peer-reviewed literature. RESULTS: Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results. CONCLUSION: SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84-94.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These compounds are currently being investigated as treatment options for hypogonadism, as they are orally administered and are relatively well-tolerated with few adverse events, though some concern exists as to whether these lead to hepatotoxicity and decreased levels of HLD cholesterol (81).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [81]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Excessive synaptic strengthening, prolonged translational disinhibition, or poorly calibrated excitability modulation could promote maladaptive plasticity, excitotoxic stress, epileptiform activity, or aberrant stabilization of pathological circuit states.”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [435]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Simon, J., Braunstein, G., Nachtigall, L., Utian, W., Katz, M., Miller, S., Waldbaum, A., Bouchard, C., Derzko, C., Buch, A., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1747 · Cited by 475
Moffat, S., Zonderman, A., Metter, E., Blackman, M. R., Harman, S., & Resnick, S. (2002) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2002-020419 · Cited by 426
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0034-6 · Cited by 403
Dobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Selective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 319
Testosterone levels and cognition in elderly men: A review
Holland, J., Bandelow, S., & Hogervorst, E. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.05.012 · Cited by 194
Vignozzi, L., Morelli, A., Sarchielli, E., Comeglio, P., Filippi, S., Cellai, I., Maneschi, E., Serni, S., Gacci, M., Carini, M., et al. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0289 · Cited by 187
Crawford, J., Prado, C. M. M., Johnston, M. A., Gralla, R. J., Taylor, R. P., Hancock, M. L., & Dalton, J. T. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0522-0 · Cited by 178
Selective estrogen receptor modulation: a personal perspective.
Jordan, V. C. (2001) · PubMed · Cited by 155
Cited by
Sorted by citations
Carboranes in drug discovery, chemical biology and molecular imaging
Marfavi, A., Kavianpour, P., & Rendina, L. M. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00400-x · Cited by 250
Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile
Basak, D., Arrighi, S., Darwiche, Y., & Deb, S. (2021) · Life · doi:10.3390/life12010048 · Cited by 240
Estrogens in adipose tissue physiology and obesity-related dysfunction
Kuryłowicz, A. (2023) · Biomedicines · doi:10.3390/biomedicines11030690 · Cited by 178
Rare ginsenosides: A unique perspective of ginseng research
Fan, W., Fan, L., Wang, Z., Mei, Y., Liu, L., Li, L., Yang, L., & Wang, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.003 · Cited by 169
Chen, H., Huang, X., Dong, M., Wen, S., Zhou, L., & Yuan, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s410834 · Cited by 185
Metadata
- Authors
- Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W.
- Affiliations
- Baylor College of Medicine (US)
- Urology Associates (US)
- Johns Hopkins University (US)
- Corresponding author
- Pastuszak, Alexander W.
- Venue
- Sexual Medicine Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01
- Volume
- 7
- Issue
- 1
- Pages
- 84-94
- ISSN
- 2050-0513 (ISSN-L)
- 2050-0521
- PMC
- PMC6326857
- OpenAlex
- W2903095656
- Cited by
- 174
- References
- 61
- Citations by year
- 2026: 18 · 2025: 19 · 2024: 30 · 2023: 28 · 2022: 36 · 2021: 20 · 2020: 16 · 2019: 7
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Sexual Medicine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- Urology Care Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Pharmacological Effects and Assays
- Keywords
- selective androgen receptor modulators, androgen receptor, anabolic steroids, cancer cachexia, benign prostatic hyperplasia, hypogonadism, breast cancer, prostate cancer, sexual desire, lean muscle mass, pharmacokinetics, pharmacodynamics
- MeSH terms
- Androgens, Breast Neoplasms, Cachexia, Clinical Trials as Topic, Female, Humans, Hypogonadism, Male, Prostatic Neoplasms, Receptors, Androgen, Androgen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
